HUTCHMED to Present New Data on HMPL-A580 at AACR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy HCM?
Source: Newsfilter
- HMPL-A580 Clinical Data Presentation: HUTCHMED will present new clinical data on HMPL-A580, a first-in-class PI3K/PIKK-EGFR antibody-targeted therapy conjugate, at the AACR 2026 Annual Meeting, demonstrating potent inhibition of PI3K and PIKK kinases with IC50 values ranging from 1 to 10 nM, indicating its potential in cancer treatment.
- Significant Anti-Tumor Effects: HMPL-A580 exhibited robust anti-tumor effects across 38 human solid tumor cell lines, particularly showing heightened sensitivity in EGFR high-expressing, EGFR-mutated, or PAM-altered tumor cells, highlighting its application prospects in precision medicine.
- Dose-Dependent Efficacy: In human tumor xenograft models in mice, HMPL-A580 demonstrated dose/exposure-dependent anti-tumor activity when administered intravenously at 1-10 mg/kg once weekly for two weeks, indicating significant target inhibition across multiple EGFR-expression models.
- Innovative ATTC Platform: HUTCHMED's ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with small-molecule inhibitors to overcome the limitations of traditional antibody-drug conjugates, aiming for more durable anti-tumor responses and improved safety profiles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCM
Wall Street analysts forecast HCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.160
Low
22.00
Averages
22.00
High
22.00
Current: 15.160
Low
22.00
Averages
22.00
High
22.00
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HUTCHMED to Present New Data on HMPL-A580 at AACR 2026
- HMPL-A580 Clinical Data Presentation: HUTCHMED will present new clinical data on HMPL-A580, a first-in-class PI3K/PIKK-EGFR antibody-targeted therapy conjugate, at the AACR 2026 Annual Meeting, demonstrating potent inhibition of PI3K and PIKK kinases with IC50 values ranging from 1 to 10 nM, indicating its potential in cancer treatment.
- Significant Anti-Tumor Effects: HMPL-A580 exhibited robust anti-tumor effects across 38 human solid tumor cell lines, particularly showing heightened sensitivity in EGFR high-expressing, EGFR-mutated, or PAM-altered tumor cells, highlighting its application prospects in precision medicine.
- Dose-Dependent Efficacy: In human tumor xenograft models in mice, HMPL-A580 demonstrated dose/exposure-dependent anti-tumor activity when administered intravenously at 1-10 mg/kg once weekly for two weeks, indicating significant target inhibition across multiple EGFR-expression models.
- Innovative ATTC Platform: HUTCHMED's ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with small-molecule inhibitors to overcome the limitations of traditional antibody-drug conjugates, aiming for more durable anti-tumor responses and improved safety profiles.
See More
HUTCHMED Initiates Phase III Trial for HMPL-760
- Trial Initiation: HUTCHMED launched a Phase III registrational clinical trial for HMPL-760 in combination with R-GemOx on March 20, 2026, marking a significant advancement in its oncology drug development pipeline.
- Efficacy Assessment: In the Phase II trial, HMPL-760 demonstrated significant improvements in objective response rate, complete response rate, progression-free survival, and overall survival compared to R-GemOx alone, with a manageable safety profile, laying a solid foundation for the Phase III study.
- Trial Scale and Objectives: The Phase III trial aims to enroll 240 patients with relapsed or refractory DLBCL, focusing on assessing progression-free survival and overall survival, intending to provide more effective treatment options in this therapeutic area.
- Financial Performance: HUTCHMED reported a net income of $456.91 million for 2025, a substantial increase from the previous year, despite a 21% decline in total oncology product revenue, with expectations for oncology/immunology revenue in the range of $330 million to $450 million for 2026, indicating ongoing competitiveness in the market.
See More
HUTCHMED Announces Withdrawal of TAZVERIK® from Chinese Market
- Market Withdrawal Announcement: HUTCHMED has initiated the withdrawal and recall of TAZVERIK® from the Chinese mainland, Hong Kong, and Macau due to Epizyme's voluntary withdrawal in the US, which significantly impacts existing patients' treatment options and underscores the company's commitment to patient safety.
- Clinical Trials Halted: The company has discontinued all active tazemetostat clinical trials, particularly the SYMPHONY-1 trial, following the Independent Data Monitoring Committee's advice that the risks of adverse events may outweigh potential benefits, affecting future research directions.
- Regulatory Collaboration: HUTCHMED is actively cooperating with regulatory authorities, including the China National Medical Products Administration and the Hong Kong Department of Health, to ensure a smooth withdrawal process, demonstrating the company's commitment to compliance and transparency.
- Limited Financial Impact: Although TAZVERIK® generated $2.5 million in sales in 2025, the withdrawal is not expected to significantly affect the company's financial guidance, indicating resilience amid market fluctuations.
See More
HUTCHMED Board Member Changes Announced
- Board Member Retirement: HUTCHMED announced that Professor Mok will retire as an Independent Non-executive Director at the upcoming AGM on May 12, 2026, marking a significant governance transition as he approaches the nine-year tenure limit.
- New Appointments Effective: Following Professor Mok's retirement, the Board approved new appointments, including Dr. Renu Bhatia as Senior and Lead Independent Non-executive Director, Dr. Chaohong Hu as Chairman of the Technical Committee, and Professor Tan Shao Weng joining the Sustainability Committee, aimed at enhancing board expertise and diversity.
- Leadership Contributions Acknowledged: HUTCHMED Chairman Dan Eldar highlighted Professor Mok's instrumental role in guiding the company's scientific and clinical development programs, underscoring the importance of leadership continuity in the company's long-term strategy.
- Compliance Statement: In accordance with Hong Kong Listing Rules, Professor Mok confirmed no disagreements with the Board and stated there are no other matters to report to shareholders, ensuring transparency and compliance in corporate governance.
See More
HUTCHMED Reports $457 Million Net Income for 2025 Amid Strategic Growth
- Significant Sales Growth: HUTCHMED reported a net income of $457 million for 2025, a substantial increase from $37.7 million in 2024, reflecting the profitability of core operations and successful non-core asset disposals, thereby enhancing the company's financial stability.
- New Technology Advancements: The Antibody-Targeted Therapy Conjugate (ATTC) platform has entered clinical trials, with the first candidate HMPL-A251 initiated in December 2025, marking rapid progress in innovative drug development and promising a rich pipeline of future candidates.
- Market Expansion Strategy: FRUZAQLA® saw a 26% increase in market sales to $366.2 million, driven by successful launches and reimbursement coverage in 38 countries, demonstrating the company's strong performance in global markets and effective response to the demand for novel non-chemotherapy treatments.
- Enhanced Financial Robustness: As of December 31, 2025, HUTCHMED's cash and short-term investments totaled $1.367 billion, supporting the accelerated development of its ATTC technology platform while providing ample funding for future innovative assets.
See More
HUTCHMED Reports FY 2023 Financial Results
- Earnings Highlights: HUTCHMED reported a GAAP EPS of $2.62 for FY 2023, indicating resilience in challenging market conditions, although it fell short of market expectations.
- Revenue Decline: The company's revenue for FY 2023 was $548.51 million, down 13% year-over-year, reflecting intensified market competition and weakened product demand, which could impact future investor confidence.
- Market Reaction: Given the revenue decline and pressure on profitability, HUTCHMED's stock price may face downward pressure, prompting investors to monitor the company's future strategic adjustments and market recovery efforts.
- Outlook: Despite the current financial underperformance, HUTCHMED must formulate effective growth strategies to address industry challenges and regain market share, ensuring long-term sustainable development.
See More
HUTCHMED to Present New Data on HMPL-A580 at AACR 2026
- HMPL-A580 Clinical Data Presentation: HUTCHMED will present new clinical data on HMPL-A580, a first-in-class PI3K/PIKK-EGFR antibody-targeted therapy conjugate, at the AACR 2026 Annual Meeting, demonstrating potent inhibition of PI3K and PIKK kinases with IC50 values ranging from 1 to 10 nM, indicating its potential in cancer treatment.
- Significant Anti-Tumor Effects: HMPL-A580 exhibited robust anti-tumor effects across 38 human solid tumor cell lines, particularly showing heightened sensitivity in EGFR high-expressing, EGFR-mutated, or PAM-altered tumor cells, highlighting its application prospects in precision medicine.
- Dose-Dependent Efficacy: In human tumor xenograft models in mice, HMPL-A580 demonstrated dose/exposure-dependent anti-tumor activity when administered intravenously at 1-10 mg/kg once weekly for two weeks, indicating significant target inhibition across multiple EGFR-expression models.
- Innovative ATTC Platform: HUTCHMED's ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with small-molecule inhibitors to overcome the limitations of traditional antibody-drug conjugates, aiming for more durable anti-tumor responses and improved safety profiles.
See More
HUTCHMED Initiates Phase III Trial for HMPL-760
- Trial Initiation: HUTCHMED launched a Phase III registrational clinical trial for HMPL-760 in combination with R-GemOx on March 20, 2026, marking a significant advancement in its oncology drug development pipeline.
- Efficacy Assessment: In the Phase II trial, HMPL-760 demonstrated significant improvements in objective response rate, complete response rate, progression-free survival, and overall survival compared to R-GemOx alone, with a manageable safety profile, laying a solid foundation for the Phase III study.
- Trial Scale and Objectives: The Phase III trial aims to enroll 240 patients with relapsed or refractory DLBCL, focusing on assessing progression-free survival and overall survival, intending to provide more effective treatment options in this therapeutic area.
- Financial Performance: HUTCHMED reported a net income of $456.91 million for 2025, a substantial increase from the previous year, despite a 21% decline in total oncology product revenue, with expectations for oncology/immunology revenue in the range of $330 million to $450 million for 2026, indicating ongoing competitiveness in the market.
See More
HUTCHMED Announces Withdrawal of TAZVERIK® from Chinese Market
- Market Withdrawal Announcement: HUTCHMED has initiated the withdrawal and recall of TAZVERIK® from the Chinese mainland, Hong Kong, and Macau due to Epizyme's voluntary withdrawal in the US, which significantly impacts existing patients' treatment options and underscores the company's commitment to patient safety.
- Clinical Trials Halted: The company has discontinued all active tazemetostat clinical trials, particularly the SYMPHONY-1 trial, following the Independent Data Monitoring Committee's advice that the risks of adverse events may outweigh potential benefits, affecting future research directions.
- Regulatory Collaboration: HUTCHMED is actively cooperating with regulatory authorities, including the China National Medical Products Administration and the Hong Kong Department of Health, to ensure a smooth withdrawal process, demonstrating the company's commitment to compliance and transparency.
- Limited Financial Impact: Although TAZVERIK® generated $2.5 million in sales in 2025, the withdrawal is not expected to significantly affect the company's financial guidance, indicating resilience amid market fluctuations.
See More
HUTCHMED Board Member Changes Announced
- Board Member Retirement: HUTCHMED announced that Professor Mok will retire as an Independent Non-executive Director at the upcoming AGM on May 12, 2026, marking a significant governance transition as he approaches the nine-year tenure limit.
- New Appointments Effective: Following Professor Mok's retirement, the Board approved new appointments, including Dr. Renu Bhatia as Senior and Lead Independent Non-executive Director, Dr. Chaohong Hu as Chairman of the Technical Committee, and Professor Tan Shao Weng joining the Sustainability Committee, aimed at enhancing board expertise and diversity.
- Leadership Contributions Acknowledged: HUTCHMED Chairman Dan Eldar highlighted Professor Mok's instrumental role in guiding the company's scientific and clinical development programs, underscoring the importance of leadership continuity in the company's long-term strategy.
- Compliance Statement: In accordance with Hong Kong Listing Rules, Professor Mok confirmed no disagreements with the Board and stated there are no other matters to report to shareholders, ensuring transparency and compliance in corporate governance.
See More
HUTCHMED Reports $457 Million Net Income for 2025 Amid Strategic Growth
- Significant Sales Growth: HUTCHMED reported a net income of $457 million for 2025, a substantial increase from $37.7 million in 2024, reflecting the profitability of core operations and successful non-core asset disposals, thereby enhancing the company's financial stability.
- New Technology Advancements: The Antibody-Targeted Therapy Conjugate (ATTC) platform has entered clinical trials, with the first candidate HMPL-A251 initiated in December 2025, marking rapid progress in innovative drug development and promising a rich pipeline of future candidates.
- Market Expansion Strategy: FRUZAQLA® saw a 26% increase in market sales to $366.2 million, driven by successful launches and reimbursement coverage in 38 countries, demonstrating the company's strong performance in global markets and effective response to the demand for novel non-chemotherapy treatments.
- Enhanced Financial Robustness: As of December 31, 2025, HUTCHMED's cash and short-term investments totaled $1.367 billion, supporting the accelerated development of its ATTC technology platform while providing ample funding for future innovative assets.
See More
HUTCHMED Reports FY 2023 Financial Results
- Earnings Highlights: HUTCHMED reported a GAAP EPS of $2.62 for FY 2023, indicating resilience in challenging market conditions, although it fell short of market expectations.
- Revenue Decline: The company's revenue for FY 2023 was $548.51 million, down 13% year-over-year, reflecting intensified market competition and weakened product demand, which could impact future investor confidence.
- Market Reaction: Given the revenue decline and pressure on profitability, HUTCHMED's stock price may face downward pressure, prompting investors to monitor the company's future strategic adjustments and market recovery efforts.
- Outlook: Despite the current financial underperformance, HUTCHMED must formulate effective growth strategies to address industry challenges and regain market share, ensuring long-term sustainable development.
See More
